【摘要】 目的探讨脑苷肌肽联合醒脑静治疗急性颅脑损伤的临床疗效。方法将104例急性颅脑损伤患者随机分两组,治疗组(n=54)在常规治疗基础上给予脑苷肌肽联合醒脑静,对照组(n=50)仅给予常规治疗,采用CT检查评估两组患者治疗前、治疗7 d后、治疗14 d后脑水肿体积的变化,同时采用格拉斯哥昏迷评分(GCS)系统及3个月后Glasgow颅脑损伤转归分级(GOS)比较两组患者的预后。结果治疗至第7天,患者脑水肿达高峰期,治疗前和治疗7天后两组患者脑水肿体积无明显统计学差异(P>0.05),但治疗14天后,治疗组患者脑水肿体积明显减少至(2.63±1.02)cm3,与对照组比较差异有统计学意义(P<0.05)。治疗后患者意识转清醒率(46.3%)显著高于对照组(P<0.05)。随访3个月,恢复良好率(42.6%)明显高于对照组(P<0.05),重残及死亡率(20.4%)明显少于对照组(P<0.05)。结论醒脑静联合脑苷肌肽能减轻神经元的损害和脑水肿,改善急性颅脑损伤病人预后,提高生存质量,降低死亡及重残率。更多还原

【Abstract】 Objective To study the clinical curative effect of brain glycosides carnosine combined with Xingnaojing injection for the treatment of acute craniocerebral injury. Methods 104 cases of acute craniocerebral injury patients were randomly divided into two groups.54 cases of the treatment group received the therapy of brain glycosides carnosine combined with Xingnaojing injection on the basis routine therapy, while 50 cases of control group received routine therapy only. CT examination was used to evaluate the change of cerebral edema volume at 7 d and 14 d of therapy, and Glasgow coma scale(GCS) system and Glasgow outcome scale(GOS) were used to compare patients’ outcome between two groups. Results At 7 d of therapy, patients’ cerebral edema reached to peak, without statistical difference in the cerebral edema volume before and 7 days after therapy between two groups(P >0.05), but at 14 d of therapy, the cerebral edema volume of treatment group decreased to(2.63 ± 1.02) cm3, significantly less than that of the control group(P <0.05). The conscious rate of the treatment group was 46.3%, significantly higher than that of the control group(P <0.05). At 3 months of follow-up, the excellent and good rate of recovery of treatment group(42.6%) was significantly higher than that of the control group(P <0.05), while the rate of severe disability and death(20.4%) was significantly lower than that of the control group(P <0.05). Conclusions For patients with acute craniocerebral injury,the combination therapy of brain glycosides carnosine and Xingnaojing injection can alleviate neuronal damage and brain edema, improve patients’ prognosis and quality of life, and reduce the rate of death and severe disability.更多还原